Key result
Completion of chemotherapy and surgery in osteosarcoma patients yielded an overall survival of 72% at 2 years and 44% at 5 years, with compliance and lung metastasis as independent prognostic factors.
Why the study?
What are the prognostic factors and survival rates for patients with osteosarcoma?
Cohort (n=163)
No
What are the prognostic factors and survival rates for patients with osteosarcoma?
In osteosarcoma patients, overall survival is significantly influenced by compliance to treatment and the presence of pulmonary metastases, rather than histological subtype or necrosis.
Answers are grounded in this paper and cite their sources.
Supports compliance emphasis in osteosarcoma care; leaves open prospective validation of prognostic factors.
AIM: Osteosarcoma is a highly malignant primary bone tumor. The study aim to evaluate the prognostic factors influencing the survival rate in our center. METHODS: This was a retrospective cohort study of all patients treated between January 2005 and December 2010. RESULTS: We included 163 patients with an age range of 6-59 years (median = 19). The median follow-up was 47 months (range 36-84). The overall survival in patients who completed chemotherapy and surgery (n = 117) was 72% at 2 years and 44% at 5 years. Histologically, 99 (85%) had osteoblastic, 6 (5%) had chondroblastic and 3 (2.5%) had telangiectatic osteosarcoma. Limb salvage surgery was performed in 80 (49%) and 41 (25%) underwent amputation. However, 46 patients (28%) underwent no surgical intervention and incomplete chemotherapy. In total, 38/79 patients had a good chemotherapy response. There was a significantly better survival rate for limb salvage versus amputation. Independent prognostic factors for survival are compliance to treatment and presence of lung metastasis. CONCLUSION: The overall survival of osteosarcoma patients was influenced by the presence of pulmonary metastases and compliance to treatment. Histological subtype, different chemotherapy regimens and histological necrosis after chemotherapy did not significantly influence survival. The patients who did not complete treatment had significantly poorer survival.
No takes yet. Share an insight, caveat, or question.
Ismail et al. (2015) conducted a cohort in Osteosarcoma (n=163). Prognostic factors (compliance to treatment, pulmonary metastases) was evaluated on Overall survival. Completion of chemotherapy and surgery in osteosarcoma patients yielded an overall survival of 72% at 2 years and 44% at 5 years, with compliance and lung metastasis as independent prognostic factors.
Synapse has enriched 10 related papers. Consider them for comparative context: